NCT06338956Completed
Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI
Source: ClinicalTrials.gov · Last updated 21 May 2025
Brief summary (registry, in English)
For the management of low-density lipoprotein-cholesterol (LDL-C), some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in LDL-C levels. High-intensity or maximally tolerated intensity can be maintained without a target goal. However, the European guideline recommends less than 55 mg/dL of LDL-C after PCI.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 135877 (actual)
- First submitted
- 24 Mar 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Samsung Medical Center
- Diseases
- Coronary artery disease
- NCT number
- NCT06338956
What you commit to
- Study type: Observational
- Participants enrolled: 135877
- From 1 Jan 2024 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving statin before PCI
Other illness
- Patients with cancer
Lab values
- Patients with LDL-C \<55 mg/dL before PCI
Other
- Patients with liver cirrhosis
- Patients without prescription of statin
Who the study is looking for
- Patients receiving PCI with health check up before and after PCI within 3 years
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.